Severe interstitial pneumonitis secondary to pegylated interferon alpha-2b and ribavirin treatment of hepatitis C infection.
Fuhrmann
Valentin
V
Department of Internal Medicine 4, General Hospital and University of Vienna, Vienna, Austria.
Kramer
Ludwig
L
Bauer
Edith
E
Laferl
Hermann
H
Tucek
Gerhard
G
Dekan
Gerhard
G
Schenk
Peter
P
D000998:Antiviral Agents / Q000009:adverse effects* / Q000627:therapeutic use; D017809:Fatal Outcome; D006526:Hepatitis C / Q000188:drug therapy*; D006801:Humans; D000077190:Interferon alpha-2; D016898:Interferon-alpha / Q000009:adverse effects* / Q000627:therapeutic use; D017563:Lung Diseases, Interstitial / Q000139:chemically induced* / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols; D011994:Recombinant Proteins; D012254:Ribavirin / Q000009:adverse effects* / Q000627:therapeutic use
D000998:Antiviral Agents; D000077190:Interferon alpha-2; D016898:Interferon-alpha; D011994:Recombinant Proteins; D011092:Polyethylene Glycols; D012254:Ribavirin; C417083:peginterferon alfa-2b